Document Detail


Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation).
MedLine Citation:
PMID:  21584696     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The new definition and risk stratification for transient ischemic attack (TIA) have clear implications for the urgency of evaluation and treatment. The optimal antithrombotic treatment for TIA is being intensively studied. New guidelines for prevention of non-cardioembolic stroke in patients with stroke or TIA recommend the use of antiplatelet agents rather than oral anticoagulation. New antiplatelet drugs are being used in cardiovascular patients, and their role in cerebrovascular patients is being studied. The impact of genetic CYP2C19 polymorphisms is becoming clarified in cardiovascular patients and it is likely these polymorphisms will affect the management of cerebrovascular patients. The results of trials of clopidogrel plus aspirin in patients with lacunar strokes and acute TIAs are forthcoming. The results of CLOSURE I, a study of a patent foramen ovale device closure trial for cryptogenic stroke or TIA, showed no differences in stroke or TIA at 2 years.
Authors:
J Donald Easton
Related Documents :
22541656 - Altered expression of cd46 and cd59 on leukocytes in neovascular age-related macular de...
21733036 - Coexistence of endometriosis and uterine septum in patients with abortion or infertility.
22701476 - Role of body mass index, waist-to-height and waist-to-hip ratio in prediction of nonalc...
22365646 - Outcome of chagas cardiomyopathy in comparison to ischemic cardiomyopathy.
10418376 - Pre-dialysis serum albumin is a poor indicator of nutritional status in stable chronic ...
11198376 - Il-1, il-4 production and ige levels in acute and chronic fasciolosis before and after ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current atherosclerosis reports     Volume:  13     ISSN:  1534-6242     ISO Abbreviation:  Curr Atheroscler Rep     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-07-06     Completed Date:  2011-12-06     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  100897685     Medline TA:  Curr Atheroscler Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  314-20     Citation Subset:  IM    
Affiliation:
Department of Neurology, University of California, San Francisco, USA. EastonJD@neurology.ucsf.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenosine / analogs & derivatives,  therapeutic use
Aryl Hydrocarbon Hydroxylases / genetics
Brain Ischemia / drug therapy*
Clinical Trials as Topic
Cytochrome P-450 Enzyme System / genetics
Fibrinolytic Agents / therapeutic use
Foramen Ovale, Patent / therapy
Genotype
Humans
Ischemic Attack, Transient / drug therapy*
Piperazines / therapeutic use
Platelet Aggregation Inhibitors / therapeutic use
Polymorphism, Genetic
Risk Assessment
Risk Factors
Stroke / drug therapy*
Tetrazoles / therapeutic use
Thiophenes / therapeutic use
Ticlopidine / analogs & derivatives,  therapeutic use
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Piperazines; 0/Platelet Aggregation Inhibitors; 0/Tetrazoles; 0/Thiophenes; 0/Ticagrelor; 34K66TBT99/prasugrel; 55142-85-3/Ticlopidine; 58-61-7/Adenosine; 9035-51-2/Cytochrome P-450 Enzyme System; A74586SNO7/clopidogrel; EC 1.14.14.1/Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1/CYP2C19 protein, human; N7Z035406B/cilostazol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Galectins as tools for glycan mapping in histology: comparison of their binding profiles to the bovi...
Next Document:  The expression of damage-regulated autophagy modulator 2 (DRAM2) contributes to autophagy induction.